PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP 599 Lexington Avenue, 36th Floor New York, NY 10022
INTERNAL RESEARCH MEMORANDUM
I. EXECUTIVE SUMMARY
This memorandum analyzes the Irish tax consequences and the United States–Ireland Income Tax Treaty (the "Treaty") implications of the proposed transfer of certain intellectual property assets (the "IP Portfolio") from Solstice Medical Technologies Inc. ("SMT Inc."), a Delaware C-corporation (EIN 84-3291507; Delaware File No. 7482916), to Solstice IP Holdings DAC ("SIP Holdings") (CRO No. 714538), an Irish designated activity company and wholly owned subsidiary of Solstice Biomedical Devices Ltd. ("SBD") (CRO No. 587241). The IP Portfolio consists of the NaviPulse catheter guidance platform and the ClearVue intra-operative cardiac imaging system, together with all associated patents, patent applications, trade secrets, know-how, engineering drawings, manufacturing process documentation, and proprietary software algorithms.
This memorandum addresses three core questions arising from the proposed transaction:
(1) Whether the IP Portfolio qualifies as a "specified intangible asset" under Section 291A of the Taxes Consolidation Act 1997 ("TCA 1997"), thereby entitling SIP Holdings to claim capital allowances (i.e., Irish tax depreciation) on the acquisition cost of the IP Portfolio;
(2) Whether the intercompany pricing for the IP transfer, the license-back arrangement, the rest-of-world licensing agreements, the contract R&D services agreement, and the intercompany loan satisfies Irish transfer pricing rules as substantially amended by Finance Act 2019; and
(3) Whether royalty payments from SMT Inc. to SIP Holdings under the proposed License-Back Agreement qualify for a 0% withholding rate under Article 12 of the Treaty, and whether SIP Holdings satisfies the Limitation on Benefits ("LOB") requirements set forth in Article 23 of the Treaty.
Summary Conclusions. At a should level of confidence, we conclude as follows:
(i) The IP Portfolio should qualify in its entirety as "specified intangible assets" under Section 291A TCA 1997, entitling SIP Holdings to annual capital allowances of approximately €13.12 million over a 15-year statutory write-off period.
(ii) The arm's-length pricing for the IP transfer and all related intercompany arrangements should satisfy Irish transfer pricing requirements under Part 35A TCA 1997 as amended by Finance Act 2019, based on the independent valuation and benchmarking analysis prepared by Whitmore Valuation Advisors LLC.
(iii) Treaty benefits should be available to SIP Holdings, reducing the US withholding tax on royalty payments from SMT Inc. to SIP Holdings under the License-Back Agreement from the statutory rate of 30% to 0%, provided that SIP Holdings maintains genuine economic substance in Ireland, qualifies as the beneficial owner of the royalty income, and satisfies at least one test under the LOB article.
Coordination with Other Advisors. This memorandum has been coordinated with, and cross-references the analyses of, the following advisors engaged in connection with this matter:
• Harrington & Cahill, Chartered Tax Advisors (led by Niamh O'Sullivan, Tax Partner), 42 Fitzwilliam Square East, Dublin 2, D02 TK83, Ireland — advising on Irish tax compliance, Revenue Commissioners matters, preparation of the Section 291A claim, and preparation of transfer pricing documentation (master file and local file).
• Dalton Byrne & Partners, Solicitors (led by Séamus Dalton, Managing Partner), 7 Earlsfort Terrace, Dublin 2, D02 PY98, Ireland — advising on Irish corporate law matters relating to the formation and governance of SIP Holdings, IP assignment documentation, and Revenue Commissioners notifications.
Exchange Rate Convention. Unless otherwise noted, all EUR/USD conversions in this memorandum use the average FY2023 exchange rate of €1 = $1.09, which is the rate applied by the client and its advisors for purposes of this transaction.
II. FACTUAL BACKGROUND
A. Transaction Parties and Corporate Structure
Solstice Biomedical Devices Ltd. ("SBD"). SBD is an Irish private company limited by shares, registered with the Companies Registration Office ("CRO") under CRO No. 587241. SBD's registered office is located at Unit 14, Corrib Technology Park, Headford Road, Galway, H91 XR72, Ireland. SBD's principal business is the design, manufacture, and distribution of minimally invasive cardiac catheter navigation systems and intra-operative imaging devices. SBD is the parent company of the group and employs approximately 1,640 employees worldwide across its global operations.
For the fiscal year ended December 31, 2023 ("FY2023"), SBD reported consolidated revenue of €347.6 million and consolidated EBITDA of €78.4 million, representing an EBITDA margin of approximately 22.5%. These figures are derived from audited consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union, audited by Pemberton Hale LLP (Aisling Brennan, Audit Partner), One Custom House Quay, Dublin 1, D01 Y6H7, Ireland.
Ownership of SBD. SBD's share capital is held as follows:
Under the terms of the shareholders' agreement governing SBD (the "SHA"), Pinnacle GEP III's prior written approval is required for material intercompany transactions exceeding €10 million. Pinnacle GEP III's investment committee (chaired by Jonathan Whitfield) has reviewed and approved the proposed IP migration transaction in principle, subject to receipt of satisfactory tax opinions and completion of definitive documentation.
Solstice Medical Technologies Inc. ("SMT Inc."). SMT Inc. is a Delaware C-corporation (EIN 84-3291507; Delaware File No. 7482916), with its principal office located at 2200 Biopharma Drive, Suite 300, Waltham, MA 02451. SMT Inc. is the US operating subsidiary of the SBD group and is responsible for research and development activities, US regulatory submissions (including FDA 510(k) clearances and PMA applications), and North American commercial operations (sales, marketing, distribution, and customer support) for the group's medical device product lines.
For FY2023, SMT Inc. reported revenue of $189.2 million, representing approximately 50.1% of SBD's consolidated revenue when converted at the average FY2023 exchange rate of €1 = $1.09. SMT Inc. employs approximately 580 employees, predominantly based at its Waltham, Massachusetts headquarters and at regional sales offices throughout the United States and Canada. For FY2023, SMT Inc. reported total deductions of $174.8 million for US federal income tax purposes.
Solstice IP Holdings DAC ("SIP Holdings"). SIP Holdings is an Irish designated activity company, registered with the CRO under CRO No. 714538. SIP Holdings was incorporated on January 18, 2024, and is registered at Unit 14, Corrib Technology Park, Headford Road, Galway, H91 XR72, Ireland—the same address as SBD's registered office. SIP Holdings' authorized and issued share capital consists of €1,000 in ordinary shares, all of which are held by SBD. SIP Holdings is a newly incorporated, special-purpose entity that has been established specifically to acquire the IP Portfolio from SMT Inc. and to serve as the centralized IP holding and licensing company for the SBD group on a going-forward basis.
B. IP Portfolio
The IP Portfolio to be transferred from SMT Inc. to SIP Holdings consists of the following intellectual property assets relating to two principal technology platforms—the NaviPulse catheter guidance platform and the ClearVue intra-operative cardiac imaging system:
• Patents: Forty-seven (47) granted United States utility patents covering core aspects of catheter navigation technology, real-time imaging processing algorithms, sensor integration, and related hardware/software architectures.
• Pending Patent Applications: Twelve (12) pending United States patent applications, including continuation and continuation-in-part applications relating to next-generation enhancements of the NaviPulse and ClearVue platforms.
• Trade Secrets and Know-How: Proprietary trade secrets, technical know-how, and manufacturing process documentation, including detailed engineering drawings, manufacturing process specifications, quality control protocols, and clinical workflow integration methodologies.
• Proprietary Software: Proprietary software algorithms underlying the NaviPulse catheter guidance system and the ClearVue imaging platform, including embedded firmware, signal-processing algorithms, and user-interface software.
Independent Valuation. The IP Portfolio has been independently valued by Whitmore Valuation Advisors LLC ("WVA"), led by Marcus Whitmore, ASA, Managing Director, under WVA project reference WVA-2023-1187. The valuation was prepared as of a valuation date of December 31, 2023, and the draft valuation report was issued on January 29, 2024. The key findings of the WVA valuation are as follows:
The WVA valuation reflects projected cash flows from the exploitation of the IP Portfolio through both the License-Back Agreement with SMT Inc. and the rest-of-world license agreements with SBD and other group entities, discounted at a WACC of 13.5% that reflects the risk profile of the medtech industry and the specific risk characteristics of the NaviPulse and ClearVue product lines.
C. Transaction Structure Summary
The proposed IP migration transaction is structured as follows:
Step 1 — IP Acquisition. SIP Holdings will acquire the entire IP Portfolio from SMT Inc. for a purchase price equal to the independently determined fair market value of $214.5 million. The purchase price will be funded through a combination of:
(a) An intercompany loan from SBD to SIP Holdings in the principal amount of €180.0 million (approximately $196.2 million at the spot exchange rate), structured with the following terms:
• Term: 10 years (maturity date: March 1, 2034).
• Interest Rate: Fixed rate of 3.75% per annum, benchmarked and supported by WVA's intercompany debt pricing analysis as an arm's-length rate for a secured intercompany loan within the SBD group.
• Annual Interest: €6.75 million (€180.0M × 3.75%).
• Repayment Schedule: Interest-only payments during Years 1 through 3; thereafter, equal annual principal installments of approximately €25.71 million (€180.0M ÷ 7) plus accrued interest for Years 4 through 10.
(b) SIP Holdings equity of €1,000 (issued share capital) plus a shareholder capital contribution from SBD in the amount of €16.7 million (approximately $18.2 million at the spot exchange rate), representing the balance of the purchase price not funded by the intercompany loan.
Step 2 — License-Back Agreement (North America). SIP Holdings will grant SMT Inc. an exclusive license (the "License-Back Agreement") for the exploitation of the IP Portfolio in North America (United States and Canada). The License-Back Agreement will provide for an arm's-length royalty of 8.0% of net sales, payable quarterly in arrears. Based on SMT Inc.'s FY2023 revenue of $189.2 million, the projected Year 1 royalty under the License-Back Agreement is $15.136 million ($189.2M × 8.0%).
Step 3 — Rest-of-World License Agreements. SIP Holdings will enter into separate license agreements with SBD and other group entities for the exploitation of the IP Portfolio in territories outside North America (the "ROW License Agreements"). The royalty rates under the ROW License Agreements will range from 4.0% to 6.5% of net sales, with the specific rate for each territory determined by reference to the functions performed, assets used, and risks assumed by the respective licensee in each territory.
Step 4 — Cost-Plus R&D Services Agreement. SMT Inc. will perform contract research and development services for SIP Holdings under a Cost-Plus R&D Services Agreement, pursuant to which SMT Inc. will be compensated at cost plus an 8.0% mark-up. Under this agreement, any intellectual property developed by SMT Inc. in the course of performing contract R&D services will be owned by SIP Holdings as the commissioning party.
Target Effective Date. The target effective date for the IP transfer and the commencement of the License-Back Agreement, the ROW License Agreements, and the Cost-Plus R&D Services Agreement is March 1, 2024.
D. Relevant Advisors and Coordination
This transaction involves multiple workstreams being handled by a team of advisors across jurisdictions. The relevant advisors and their respective roles are as follows:
• Calderwood & Harkness LLP (this firm) — US tax analysis, including IRC § 367(d), § 482, GILTI, Subpart F, BEAT, and US-Ireland Treaty analysis. This memorandum addresses the Irish tax and Treaty aspects of the transaction. The US-side analysis is set forth in companion memoranda described in Section VII below.
• Harrington & Cahill, Chartered Tax Advisors — Niamh O'Sullivan, Tax Partner, 42 Fitzwilliam Square East, Dublin 2, D02 TK83, Ireland. Responsible for Irish tax compliance and Revenue Commissioners filings, preparation of the Section 291A claim, and preparation of transfer pricing documentation (master file and local file) under Section 835E TCA 1997. This memorandum has been coordinated with Harrington & Cahill's analysis of the Irish domestic tax consequences of the transaction.
• Dalton Byrne & Partners, Solicitors — Séamus Dalton, Managing Partner, 7 Earlsfort Terrace, Dublin 2, D02 PY98, Ireland. Responsible for Irish corporate law advice on SIP Holdings' formation and governance, IP assignment documentation (including the instruments of assignment for each of the 47 US utility patents and 12 pending applications), and Revenue Commissioners notifications. Dalton Byrne & Partners has confirmed that the IP assignment documentation will be prepared to comply with all applicable Irish law requirements.
• Lattimore & Stern CPAs LLP — David Lattimore, CPA, Partner, 155 Federal Street, Suite 1400, Boston, MA 02110. Responsible for US federal and state income tax return preparation for SMT Inc., including reporting of the IP transfer under IRC § 367(d), US withholding compliance (Forms W-8BEN-E, 1042, 1042-S), and coordination with the IRS as necessary.
• Pemberton Hale LLP — Aisling Brennan, Audit Partner, One Custom House Quay, Dublin 1, D01 Y6H7, Ireland. Statutory auditor of the SBD group; responsible for the audit of SBD's consolidated financial statements and the financial statements of SIP Holdings following the IP transfer.
III. SECTION 291A TCA 1997 — CAPITAL ALLOWANCES ON SPECIFIED INTANGIBLE ASSETS
A. Overview of the Irish Intangible Asset Amortization Regime
Section 291A of the Taxes Consolidation Act 1997 provides a statutory framework under which Irish-resident companies may claim capital allowances (i.e., tax depreciation) on qualifying expenditure incurred on the acquisition of "specified intangible assets" for the purposes of a trade carried on by the company. This regime, commonly referred to as the "knowledge development box" capital allowances regime (though distinct from the separate "Knowledge Development box" relief under Section 769R TCA 1997), was introduced by Finance Act 2009 and has been amended on several occasions since.
The core features of the regime are as follows:
Eligible Assets. Section 291A(1) TCA 1997 sets forth an exhaustive statutory list of "specified intangible assets" that qualify for capital allowances under the regime. The list includes, inter alia:
(a) patents and patent rights;
(b) registered designs;
(c) trademarks;
(d) copyright;
(e) know-how (within the meaning of Section 768 TCA 1997);
(f) supplementary protection certificates;
(g) plant breeders' rights;
(h) authorizations within the meaning of various EU pharmaceutical directives;
(i) rights under the law of any territory corresponding to the foregoing; and
(j) goodwill directly attributable to any of the foregoing specified intangible assets.
Capital Allowances Computation. Capital allowances on specified intangible assets are available to the claimant company on one of two bases, at the company's election:
(a) In line with accounting amortization: the company may claim capital allowances in each accounting period in an amount equal to the amortization or impairment charge recognized in respect of the specified intangible asset in the company's profit and loss account prepared in accordance with generally accepted accounting practice; or
(b) Over a fixed statutory write-off period of 15 years: the company may claim capital allowances at a rate of one-fifteenth (1/15th) of the qualifying expenditure per annum, irrespective of the accounting treatment.
The election between the two methods is generally made in the company's first Corporation Tax return in which capital allowances on the relevant specified intangible assets are claimed, and once made, is irrevocable for the relevant assets.
80% Income Cap. Section 291A(4) TCA 1997 imposes an important limitation: the aggregate of (i) capital allowances on specified intangible assets and (ii) any related interest expense (i.e., interest on borrowings used to fund the acquisition of the specified intangible assets) that may be deducted against income of the relevant trade in any accounting period is capped at 80% of the trading income of that trade (before such allowances and interest). The remaining 20% of trading income is thus always subject to Irish corporation tax. This cap is a critical consideration in structuring the acquisition financing and in projecting the effective Irish tax rate on SIP Holdings' income.
Qualifying Trade. The claimant company must be carrying on a trade for the purposes of which the specified intangible assets are used. The exploitation, management, and licensing of intellectual property constitutes a "trade" for Irish tax purposes, provided the company has genuine economic substance in Ireland and is actively engaged in the management of its IP portfolio.
B. Qualification of the Transferred IP as a "Specified Intangible Asset"
A threshold question for this analysis is whether the IP Portfolio to be transferred from SMT Inc. to SIP Holdings falls within the statutory definition of "specified intangible assets" under Section 291A(1) TCA 1997. We address each category of IP in turn.
Granted US Utility Patents (47). Patents and patent rights are expressly enumerated in the statutory list of specified intangible assets under Section 291A(1)(a) TCA 1997. Although the 47 granted patents in the IP Portfolio are US utility patents (i.e., granted by the United States Patent and Trademark Office under Title 35 of the United States Code), they constitute "rights under the law of any territory" corresponding to Irish or EU patents and thus clearly fall within the scope of Section 291A. There is no requirement that the patents be Irish or European patents; foreign patents are expressly included. Accordingly, the 47 granted US utility patents should qualify without difficulty as specified intangible assets.
Pending US Patent Applications (12). The characterization of pending patent applications presents a slightly more nuanced question. A pending patent application is not yet a granted patent; it represents a contingent right that may or may not ripen into a granted patent, depending on the outcome of the examination process before the relevant patent office. Under a strict reading, pending patent applications may not constitute "patents" within the meaning of Section 291A(1)(a). However, we note two alternative bases on which pending patent applications should nonetheless fall within the scope of Section 291A:
First, to the extent that a pending patent application embodies technical know-how and proprietary information, it may be characterized as "know-how" within the meaning of Section 768 TCA 1997 (which defines know-how broadly as "any industrial information and techniques likely to assist in the manufacture or processing of goods or materials"), which is cross-referenced in Section 291A(1). On this basis, the pending applications should qualify as specified intangible assets in their own right, irrespective of their patent status.
Second, the pending applications are inextricably bundled with the granted patents and the broader trade secrets and know-how in the IP Portfolio. In the context of a portfolio acquisition, the Revenue Commissioners have generally accepted that the entire portfolio of related IP assets acquired as a package constitutes specified intangible assets, provided the predominant character of the portfolio falls within Section 291A.
In either case, the pending patent applications should fall within the scope of Section 291A, and we do not anticipate a challenge from the Revenue Commissioners on this point.
Trade Secrets, Technical Know-How, and Manufacturing Process Documentation. Section 291A(1) expressly includes "know-how" within the meaning of Section 768 TCA 1997 in the list of specified intangible assets. Section 768 defines "know-how" as "any industrial information and techniques likely to assist in the manufacture or processing of goods or materials." The trade secrets, technical know-how, engineering drawings, and manufacturing process documentation included in the IP Portfolio clearly satisfy this definition, as they relate directly to the design, manufacture, and quality control of the NaviPulse and ClearVue medical device platforms. Accordingly, these assets should qualify as specified intangible assets under Section 291A.
Proprietary Software Algorithms. The proprietary software algorithms underlying the NaviPulse and ClearVue platforms may qualify as specified intangible assets on either of two bases: (i) as "copyright" under Section 291A(1)(d), to the extent that the software is protected by copyright under Irish or US law (as is typically the case for original software code), or (ii) as "know-how" under Section 768, to the extent that the algorithms embody industrial techniques likely to assist in the manufacture or processing of goods (which is arguably the case for algorithms embedded in medical device firmware and signal-processing systems). In either case, the software algorithms should fall within the scope of Section 291A.
Conclusion. Based on the foregoing analysis, the transferred IP Portfolio should, in its entirety, constitute "specified intangible assets" for purposes of Section 291A TCA 1997. Each category of IP in the portfolio—granted patents, pending patent applications, trade secrets and know-how, manufacturing documentation, and proprietary software—falls within one or more of the enumerated categories in Section 291A(1).
C. Computation of Capital Allowances
The qualifying expenditure incurred by SIP Holdings on the acquisition of the IP Portfolio is equal to the arm's-length purchase price of $214.5 million, converted at the average FY2023 exchange rate of €1 = $1.09, yielding a qualifying expenditure of approximately €196.8 million.
We recommend that SIP Holdings elect the 15-year statutory write-off period (rather than aligning capital allowances with accounting amortization) for the following reasons: (i) the 15-year statutory period provides certainty and predictability in annual deductions, eliminating the risk that changes in accounting estimates of useful life could affect the timing of allowances; (ii) a fixed annual deduction facilitates tax planning and cash flow forecasting; and (iii) the statutory method avoids potential complications arising from differences between Irish GAAP amortization and the useful life determined by WVA.
Under the 15-year statutory write-off period, SIP Holdings' annual capital allowance will be:
€196.8 million ÷ 15 = approximately €13.12 million per year
Relationship to WVA's Estimated Useful Life. WVA has estimated the remaining weighted-average useful life of the IP Portfolio at 12.8 years. The 15-year statutory write-off period exceeds this estimate by approximately 2.2 years, meaning that capital allowances will continue to be claimed for approximately 2.2 years after the IP Portfolio's estimated useful life has been fully exhausted. This is permissible under the statute, which imposes a fixed 15-year period regardless of the actual or estimated useful life of the underlying assets. There is no requirement that the capital allowance period match the economic useful life.
80% Income Cap Analysis. Under Section 291A(4), the aggregate of capital allowances (€13.12 million per annum) and related interest deductions on the intercompany loan from SBD (€6.75 million per annum) cannot exceed 80% of SIP Holdings' trading income from the relevant trade in any accounting period. The combined annual deductions are €19.87 million (€13.12M + €6.75M). In order for SIP Holdings to fully absorb these deductions, its trading income (before such deductions) must equal or exceed:
€19.87 million ÷ 0.80 = approximately €24.84 million
SIP Holdings' projected trading income will consist of:
• Royalty receipts from SMT Inc. under the License-Back Agreement: projected Year 1 royalty of $15.136 million ≈ €13.89 million (at €1 = $1.09).
• Royalty receipts from SBD and other group entities under the ROW License Agreements, at rates of 4.0%–6.5% of net sales. Based on FY2023 rest-of-world revenue of approximately €158.4 million (€347.6M consolidated less $189.2M/1.09 ≈ €173.6M for SMT Inc., adjusted for intercompany eliminations), projected ROW royalty income is estimated in the range of €6.3 million to €10.3 million, depending on the applicable rate mix.
• Total projected Year 1 trading income: approximately €20.2 million to €24.2 million, depending on the ROW royalty rate mix and revenue growth assumptions.
The above projections suggest that SIP Holdings' Year 1 trading income may be at or near the threshold of €24.84 million required for full absorption of the combined capital allowances and interest deductions. In Years 2 and beyond, revenue growth in both North America and rest-of-world markets is expected to increase trading income above the threshold. We note that detailed financial projections for SIP Holdings have been prepared by Harrington & Cahill (Niamh O'Sullivan) in connection with the Section 291A claim, and those projections should be cross-referenced for a more granular analysis of the 80% cap in each projected accounting period.
To the extent that the 80% cap limits the deduction of capital allowances in any given year, unused capital allowances are not lost but rather carry forward to subsequent accounting periods. Nevertheless, from a tax planning perspective, it is desirable to structure the transaction so that the 80% cap is not binding, in order to maximize the present-value benefit of the capital allowances.
Qualifying Trade Requirement. SIP Holdings must demonstrate that it is carrying on a "qualifying trade" for Irish tax purposes—specifically, a trade that consists of the exploitation, management, and licensing of intellectual property. As discussed in Section III.D below, SIP Holdings will maintain genuine economic substance in Ireland, including dedicated employees and Irish-based decision-making authority, which should be sufficient to establish that SIP Holdings is carrying on a qualifying trade. The Revenue Commissioners have generally accepted that the active management and licensing of IP constitutes a trade, provided the company has substance and does not function as a mere passive conduit.
Coordination Note. Harrington & Cahill (Niamh O'Sullivan) is responsible for preparing the Section 291A claim for submission to the Irish Revenue Commissioners. The claim will be filed with SIP Holdings' first Corporation Tax return (Form CT1) for the accounting period in which the IP transfer takes effect. Harrington & Cahill will ensure that the appropriate election for the 15-year statutory write-off method is properly documented and filed.
D. Substance Requirements
The availability of Section 291A capital allowances, and indeed the broader tax treatment of SIP Holdings as an Irish tax-resident company carrying on a qualifying trade in Ireland, depends critically on SIP Holdings maintaining genuine economic substance in Ireland. The key substance requirements are as follows:
Central Management and Control. SIP Holdings must be centrally managed and controlled in Ireland in order to be treated as Irish tax resident. Under Irish common law principles (as codified by Section 23A TCA 1997 for companies incorporated in Ireland on or after January 1, 2015), a company incorporated in Ireland is treated as resident in Ireland unless it is treated as resident in a treaty partner jurisdiction by reason of that jurisdiction's domestic law and by application of a tie-breaker provision in an applicable tax treaty. For SIP Holdings (incorporated in Ireland in 2024), Irish tax residence is presumed, but could be challenged if it were demonstrated that central management and control was effectively exercised outside Ireland.
Irish-Resident Directors. SIP Holdings should have a majority of Irish-resident directors (or at minimum, a sufficient number to ensure that board decisions are genuinely made in Ireland). We understand from SBD's representations that SIP Holdings' board will include at least two Irish-resident directors with relevant industry experience.
Registered Office and Physical Presence. SIP Holdings' registered office is located at Unit 14, Corrib Technology Park, Headford Road, Galway, H91 XR72, Ireland. This is confirmed by the CRO filings prepared by Dalton Byrne & Partners.
Board Meetings. All meetings of SIP Holdings' board of directors should be held in Ireland. Minutes should reflect substantive discussion and decision-making on matters relating to the IP Portfolio, including licensing strategy, enforcement decisions, R&D oversight, and commercial terms.
Dedicated Employees. SIP Holdings should have employees or dedicated personnel in Ireland responsible for the active management of the IP Portfolio. Based on representations received from SBD in a letter dated March 8, 2024, signed by Fiona Gallagher (CFO) and Dr. Cathal Morrissey (CEO), SIP Holdings will employ dedicated staff at its Galway offices who will be responsible for the following functions:
• Strategic oversight and management of the IP Portfolio, including patent prosecution strategy and renewal decisions;
• Negotiation and management of license agreements with group entities and potential third-party licensees;
• Oversight of contract R&D services performed by SMT Inc. under the Cost-Plus R&D Services Agreement;
• Monitoring and enforcement of IP rights; and
• Financial management and reporting.
All strategic IP management decisions—including decisions relating to the prosecution, maintenance, enforcement, licensing, and disposition of IP—will be made in Ireland by SIP Holdings' Irish-based personnel and board of directors.
Dalton Byrne & Partners Confirmation. Dalton Byrne & Partners (Séamus Dalton) has confirmed that SIP Holdings' constitutional documents (Memorandum and Articles of Association) and corporate governance framework are structured to support Irish management and control. The constitutional documents include provisions requiring that board meetings be held in Ireland and that a majority of directors be Irish-resident.
Key Risk. If the Irish Revenue Commissioners were to determine that SIP Holdings lacks genuine economic substance, or that management and control is effectively exercised outside Ireland (e.g., that key decisions are made by Pinnacle GEP III in New York or by SMT Inc. personnel in Waltham), the consequences could be severe:
• Section 291A capital allowances could be denied on the basis that SIP Holdings is not carrying on a qualifying trade in Ireland;
• SIP Holdings could be treated as non-resident for Irish tax purposes, with potential adverse consequences for the availability of Treaty benefits; and
• The Revenue Commissioners could challenge the overall transfer pricing of the intercompany arrangements on the basis that SIP Holdings does not perform sufficient functions, use sufficient assets, or assume sufficient risks to justify the royalty income it receives.
We therefore emphasize that the maintenance of genuine economic substance in Ireland is a foundational requirement for the success of the proposed IP migration structure.
E. Interaction with the Intercompany Loan
The intercompany loan from SBD to SIP Holdings in the principal amount of €180.0 million at a fixed interest rate of 3.75% per annum generates annual interest expense for SIP Holdings of €6.75 million. This interest expense is relevant to the Section 291A analysis in two respects.
80% Cap on Combined Deductions. As discussed in Section III.C above, Section 291A(5) TCA 1997 provides that the 80% income cap applies to the aggregate of capital allowances claimed under Section 291A and "related interest" (i.e., interest on borrowings the proceeds of which were used to acquire the specified intangible assets). The intercompany loan from SBD to SIP Holdings was used to fund the acquisition of the IP Portfolio, and the interest on that loan is therefore "related interest" within the meaning of Section 291A(5).
The combined annual deductions subject to the 80% cap are:
As computed in Section III.C, SIP Holdings' trading income must equal or exceed approximately €24.84 million for the 80% cap to be non-binding. We recommend monitoring this threshold annually.
Arm's-Length Character of the Interest Rate. The interest rate on the intercompany loan (3.75% fixed) must be arm's-length under Irish transfer pricing rules (discussed further in Section IV below). WVA has prepared an intercompany debt pricing analysis that benchmarks the 3.75% rate against comparable third-party lending transactions and demonstrates that it falls within the arm's-length range. The Revenue Commissioners may scrutinize this rate, particularly given the substantial principal amount of the loan and the fact that SIP Holdings is a newly incorporated entity with no independent credit history. WVA's analysis takes into account the implicit credit support provided by SBD as the parent company and the security provided by the IP Portfolio itself.
F. Clawback Provisions
Sections 291A(6) and (7) of TCA 1997 contain clawback provisions that apply if specified intangible assets in respect of which capital allowances have been claimed are disposed of within a specified period. In broad terms, the clawback provisions require the claimant company to recognize a balancing charge (i.e., a recapture of previously claimed capital allowances) in the event that the specified intangible assets are sold, transferred, or otherwise disposed of.
SIP Holdings does not currently intend to dispose of any part of the IP Portfolio. However, we note the following considerations:
• In the event that Pinnacle GEP III seeks to exit its investment in SBD (whether by trade sale, IPO, or secondary transaction), any restructuring of the SBD group that involves a transfer of the IP Portfolio from SIP Holdings to another entity could trigger the clawback provisions.
• Similarly, if SIP Holdings grants a perpetual, exclusive license of the IP Portfolio to a third party (or to a group entity outside Ireland) on terms that effectively transfer the economic ownership of the IP, the Revenue Commissioners could argue that a "disposal" has occurred for purposes of the clawback provisions.
We recommend that SBD and its advisors carefully consider the Section 291A clawback provisions in connection with any future restructuring, exit planning, or change-of-control scenario. Harrington & Cahill should be consulted on the mechanics and computation of any potential clawback.
IV. IRISH TRANSFER PRICING COMPLIANCE
A. Overview of Irish TP Rules — Finance Act 2019 Amendments
Ireland's transfer pricing regime underwent a significant overhaul as part of the Finance Act 2019, which introduced comprehensive amendments to Part 35A of the TCA 1997, effective for chargeable periods commencing on or after January 1, 2020. The amended rules represent a substantial expansion and modernization of Ireland's transfer pricing framework, bringing it broadly into alignment with international best practices, including the OECD Transfer Pricing Guidelines (2022 edition, which replaced the 2017 edition and incorporates the BEPS Actions 8–10 final reports on intangibles, risks, and capital).
The key features of the amended Irish transfer pricing regime relevant to the proposed transaction are:
Arm's-Length Principle. Part 35A TCA 1997 requires that arrangements between associated persons (as defined) be conducted on terms that would be agreed between independent parties dealing at arm's length. Where the terms of an arrangement between associated persons deviate from arm's-length terms, the Irish Revenue Commissioners may adjust the profits of one or both parties to reflect the arm's-length outcome.
Expanded Scope. Prior to the Finance Act 2019 amendments, Irish transfer pricing rules applied only to trading transactions between associated persons. The amended rules extend the scope to cover:
• Both trading and non-trading transactions;
• Capital transactions, including the transfer of intangible assets between associated persons; and
• Transactions involving entities that are not Irish-resident but have an Irish branch or permanent establishment.
The extension to capital transactions is particularly relevant to the proposed IP transfer, which involves the sale of the IP Portfolio from SMT Inc. to SIP Holdings at a purchase price of $214.5 million.
Alignment with OECD Guidelines. The amended rules provide that the arm's-length principle is to be applied in accordance with the OECD Transfer Pricing Guidelines, including the guidance on the transfer pricing of intangible assets (Chapter VI), the allocation of risks and capital (Chapter I, Part D), and the application of the transactional profit methods.
Mandatory Documentation. Section 835E TCA 1997 introduces mandatory transfer pricing documentation requirements, broadly aligned with the OECD's three-tier documentation framework (master file, local file, and country-by-country report). These requirements are discussed in Section IV.D below.
B. Application to the IP Transfer
The transfer of the IP Portfolio from SMT Inc. to SIP Holdings at a purchase price of $214.5 million constitutes a capital transaction between associated persons (SMT Inc. and SIP Holdings are both wholly owned, directly or indirectly, by SBD). The purchase price must be demonstrated to be arm's-length for Irish transfer pricing purposes.
WVA Independent Valuation. The primary evidentiary support for the arm's-length character of the $214.5 million purchase price is the independent valuation prepared by Whitmore Valuation Advisors LLC (WVA project reference WVA-2023-1187). The WVA valuation employs the income approach / DCF methodology, which is generally regarded as the most appropriate method for valuing unique, income-producing intangible assets. The key assumptions underlying the valuation—including the revenue projections, cost assumptions, discount rate (13.5% WACC), and remaining useful life (12.8 years)—have been reviewed by both Calderwood & Harkness and Harrington & Cahill and are considered reasonable based on the available market data and the specific characteristics of the NaviPulse and ClearVue product lines.
The OECD Transfer Pricing Guidelines (Chapter VI, Section D) recognize the income approach as an appropriate method for valuing intangible assets in transfer pricing contexts, provided the assumptions are reasonable and the analysis is conducted with appropriate rigor. WVA's analysis satisfies these requirements.
Benchmarking of the 8.0% Royalty Rate. In addition to the lump-sum valuation of the IP Portfolio, WVA has benchmarked the 8.0% royalty rate for the License-Back Agreement against comparable uncontrolled transactions ("CUTs") in the medtech sector. WVA identified a set of comparable licensing agreements between independent parties involving similar medical device technologies and applied appropriate comparability adjustments to derive an arm's-length range. The 8.0% rate falls within the interquartile range of the adjusted comparables. This benchmarking analysis should satisfy both US and Irish transfer pricing requirements for the ongoing royalty payments.
Internal Consistency. The relationship between the lump-sum purchase price ($214.5 million) and the ongoing royalty rate (8.0%) must be internally consistent—that is, the present value of the projected royalty stream, discounted at an appropriate rate, should be broadly consistent with the lump-sum valuation. WVA has confirmed that its valuation model demonstrates this internal consistency.
C. Application to Ongoing Intercompany Transactions
In addition to the one-time IP transfer, the proposed structure involves several ongoing intercompany arrangements, each of which must satisfy Irish transfer pricing requirements on a continuing basis:
License-Back Agreement (SMT Inc. — 8.0% of net sales). The royalty rate of 8.0% of net sales payable by SMT Inc. to SIP Holdings under the License-Back Agreement has been benchmarked by WVA against CUTs, as described above. The royalty rate should be reviewed periodically (at least annually) to ensure it remains within the arm's-length range as the underlying facts and circumstances evolve. We recommend that Harrington & Cahill incorporate an annual compliance monitoring process into SIP Holdings' transfer pricing documentation procedures.
ROW License Agreements (4.0%–6.5% of net sales). The royalty rates under the ROW License Agreements vary by territory, ranging from 4.0% to 6.5% of net sales. This variation reflects differences in the functions performed, assets used, and risks assumed by the respective licensees in each territory. For example, licensees that perform significant marketing and distribution functions, assume inventory and credit risk, and incur substantial local regulatory compliance costs may be charged lower royalty rates than licensees that perform more limited functions. The WVA benchmarking analysis supports the range of 4.0%–6.5% as arm's-length, but each territory-specific rate should be individually documented with reference to the specific functional and risk profile of the relevant licensee.
Cost-Plus R&D Services Agreement (cost + 8.0%). Under the Cost-Plus R&D Services Agreement, SMT Inc. will perform contract R&D services for SIP Holdings and will be compensated at cost plus an 8.0% mark-up. The 8.0% mark-up should be documented with reference to comparable benchmarks for contract R&D services in the medtech sector. WVA has identified a set of comparable service arrangements between independent parties and has confirmed that the 8.0% mark-up falls within the arm's-length range for routine contract R&D services. We note, however, that the characterization of SMT Inc.'s R&D activities as "routine" contract services (as opposed to entrepreneurial R&D involving the assumption of significant development risk) is a factual determination that may be subject to scrutiny by the Revenue Commissioners. The functional analysis should clearly demonstrate that SIP Holdings, as the IP owner, bears the economic risk of R&D outcomes and exercises strategic control over the R&D program.
Intercompany Loan (€180.0 million at 3.75% fixed). The interest rate on the intercompany loan from SBD to SIP Holdings (3.75% per annum, fixed) must be arm's-length. WVA has prepared an intercompany debt pricing analysis that benchmarks the rate against comparable third-party lending transactions, taking into account factors such as the borrower's creditworthiness, the loan term, the security arrangements, and prevailing market interest rates. We note that the Irish Revenue Commissioners may also scrutinize whether the intercompany loan should be recharacterized as equity under thin capitalization or debt/equity principles. The debt-to-equity ratio of SIP Holdings following the transaction will be approximately 10.8:1 (€180.0 million debt vs. approximately €16.7 million equity contribution plus €1,000 share capital), which is high by any standard. While Ireland does not currently have a standalone statutory thin capitalization rule, the Revenue Commissioners have the power under the general anti-avoidance provision (Section 811C TCA 1997) and under Part 35A to recharacterize debt as equity if the terms of the financing arrangement would not be agreed between independent parties. The WVA intercompany debt pricing analysis should address this risk by demonstrating that the loan terms (including the debt-to-equity ratio) are consistent with what an independent lender would accept, given the nature and quality of the underlying IP as collateral.
D. Documentation Requirements
Section 835E TCA 1997, as introduced by Finance Act 2019, imposes mandatory transfer pricing documentation requirements on Irish-resident companies that are parties to arrangements with associated persons. The documentation requirements are broadly aligned with the OECD's three-tier documentation framework:
Master File. A master file containing group-level information about the SBD group's organizational structure, business operations, intangible assets, intercompany financial activities, and global tax positions. The master file should cover all material intercompany arrangements within the group, including the IP transfer, the License-Back Agreement, the ROW License Agreements, the Cost-Plus R&D Services Agreement, and the intercompany loan.
Local File. A local file containing entity-level transactional documentation for SIP Holdings, including:
• A detailed description of each controlled transaction in which SIP Holdings is a party;
• A functional analysis identifying the functions performed, assets used, and risks assumed by each party to each controlled transaction;
• The transfer pricing method selected and the reasons for its selection;
• The comparable transactions or companies used as benchmarks, and the analysis supporting the arm's-length character of the pricing;
• A copy of the WVA valuation report and intercompany debt pricing analysis; and
• Financial data and projections used in the analysis.
Country-by-Country Report ("CbCR"). If SBD meets the revenue threshold for CbCR filing (consolidated group revenue of €750 million or more), it must file a CbCR with the Irish Revenue Commissioners. Based on SBD's FY2023 consolidated revenue of €347.6 million, SBD does not currently meet this threshold and is not required to file a CbCR. This should be monitored annually in the event that SBD's revenue grows above the threshold.
Timing and Availability. Transfer pricing documentation must be contemporaneous—that is, it must be prepared at or around the time the relevant transactions are entered into—and must be available at the time SIP Holdings files its Corporation Tax return (Form CT1) for the relevant accounting period. Failure to maintain adequate documentation can result in penalties and may shift the burden of proof to the taxpayer in the event of a Revenue audit.
Coordination. Harrington & Cahill (Niamh O'Sullivan) is preparing the master file and local file documentation for SIP Holdings. Calderwood & Harkness's US-side transfer pricing analysis (set forth in a companion memorandum on IRC § 482, Matter No. 1037-00007) will be coordinated with Harrington & Cahill to ensure consistency in methodologies, conclusions, and supporting data across both jurisdictions. Consistency between the US and Irish transfer pricing positions is critical to minimizing the risk of double taxation and to presenting a unified position in the event of audits by either the IRS or the Irish Revenue Commissioners.
E. Conclusion on Irish TP
Based on the independent WVA valuation and benchmarking analysis, the structure and pricing of the intercompany arrangements should satisfy Irish transfer pricing requirements under Part 35A TCA 1997 as amended by Finance Act 2019. Specifically:
• The $214.5 million purchase price for the IP Portfolio should be supportable as arm's-length based on the WVA income approach / DCF valuation.
• The 8.0% royalty rate under the License-Back Agreement with SMT Inc. should be supportable as arm's-length based on WVA's CUT benchmarking analysis.
• The range of 4.0%–6.5% for ROW license royalties should be supportable as arm's-length, provided each territory-specific rate is individually documented with reference to the functional and risk profile of the relevant licensee.
• The cost + 8.0% mark-up under the Cost-Plus R&D Services Agreement should be supportable as arm's-length based on comparable benchmarks for contract R&D services in the medtech sector.
• The 3.75% fixed interest rate on the intercompany loan should be supportable as arm's-length based on WVA's intercompany debt pricing analysis, although the high debt-to-equity ratio of SIP Holdings warrants careful documentation to address potential recharacterization risk.
The foregoing conclusions are subject to the maintenance of adequate and contemporaneous transfer pricing documentation, as described in Section IV.D above.
V. US-IRELAND INCOME TAX TREATY — ROYALTY WITHHOLDING AND LIMITATION ON BENEFITS
A. Article 12 — Royalties: Withholding Rate Reduction
Statutory Withholding Rate. Under the Internal Revenue Code, royalty payments from a US person to a foreign person are generally classified as "fixed or determinable annual or periodical" ("FDAP") income and are subject to US withholding tax at a statutory rate of 30% under IRC § 1441 and § 1442. Absent an applicable income tax treaty, SMT Inc. (as the payor and withholding agent) would be required to withhold 30% of each royalty payment made to SIP Holdings under the License-Back Agreement.
Treaty Reduction. Article 12 of the Convention between the Government of the United States of America and the Government of Ireland for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital Gains (the "Treaty"), signed on July 28, 1997, and entered into force on December 17, 1997, provides a preferential withholding rate for royalties paid by a US resident to a resident of Ireland.
Specifically, Article 12(1) of the Treaty provides:
"Royalties arising in a Contracting State and beneficially owned by a resident of the other Contracting State shall be taxable only in that other State."
This provision means that royalties arising in the United States (i.e., royalties paid by SMT Inc.) and beneficially owned by a resident of Ireland (i.e., SIP Holdings, assuming it qualifies as an Irish resident and beneficial owner) shall be taxable only in Ireland. The effect is to reduce the US withholding rate on such royalties from 30% to 0%.
Definition of "Royalties." Article 12(2) of the Treaty defines "royalties" broadly to include:
"payments of any kind received as a consideration for the use of, or the right to use, any copyright of literary, artistic, or scientific work including cinematograph films, any patent, trade mark, design or model, plan, secret formula or process, or for information concerning industrial, commercial, or scientific experience."
The payments under the License-Back Agreement—specifically, the 8.0% royalty on net sales payable by SMT Inc. to SIP Holdings for the right to use the IP Portfolio (comprising patents, trade secrets, know-how, and proprietary software) in North America—fall squarely within this definition. The payments constitute consideration for the use of patents and for information concerning industrial experience, and thus qualify as "royalties" within the meaning of Article 12.
Beneficial Ownership Requirement. The 0% withholding rate under Article 12(1) is available only if SIP Holdings is the "beneficial owner" of the royalties. The concept of beneficial ownership in the treaty context generally requires that the payee have the right to use and enjoy the royalty income, and not be acting merely as an agent, nominee, or conduit obligated to pass the income through to another party.
SIP Holdings should satisfy the beneficial ownership requirement based on the following factors:
• SIP Holdings will be the legal and beneficial owner of the underlying IP Portfolio, having acquired it from SMT Inc. for valuable consideration.
• SIP Holdings will have entered into the License-Back Agreement on its own behalf and in its own right as the IP owner.
• SIP Holdings will receive the royalty payments and will have the right to use and enjoy the income—it will not be contractually or legally obligated to pass the royalty income through to any other person (other than in satisfaction of its ordinary commercial obligations, such as interest payments on the intercompany loan from SBD).
• SIP Holdings will have economic substance in Ireland, including dedicated employees, Irish-resident directors, and decision-making authority over IP management and licensing matters.
Based on the foregoing, SIP Holdings should qualify as the beneficial owner of the royalty payments under the License-Back Agreement.
Conclusion. Royalty payments from SMT Inc. to SIP Holdings under the License-Back Agreement should qualify for a 0% US withholding rate under Article 12 of the US-Ireland Income Tax Treaty, provided SIP Holdings is treated as a resident of Ireland for Treaty purposes, qualifies as the beneficial owner of the royalties, and satisfies the LOB requirements discussed in Section V.B below.
B. Limitation on Benefits (LOB) — Article 23
Overview. Article 23 of the Treaty contains a Limitation on Benefits ("LOB") provision designed to prevent "treaty shopping"—i.e., the use of the Treaty by persons who are not genuinely connected to Ireland to obtain the reduced withholding rates and other benefits provided by the Treaty. The LOB article requires that a resident of Ireland claiming Treaty benefits satisfy at least one of several objective tests demonstrating a genuine connection to Ireland.
SIP Holdings, as a newly incorporated Irish company that will serve as the centralized IP holding and licensing entity for the SBD group, must satisfy at least one LOB test to be entitled to Treaty benefits. We analyze the most relevant tests below.
1. Ownership and Base Erosion Test (Article 23(2)(e))
The ownership and base erosion test under Article 23(2)(e) of the Treaty generally provides that a company resident in Ireland is a "qualified person" entitled to Treaty benefits if: